Alentis Therapeutics is a clinical stage biotechnology company that focuses on developing breakthrough treatments for fibrotic diseases and associated cancers.
Alentis is using its portfolio of unique monoclonal antibodies that are highly selective for exposed and non-junctional Claudin-1.
Claudin-1 a previously unexploited target that plays a key role in the pathology of fibrosis across organs as well as solid tumors.
Alentis Therapeutics
